Medicine
Romvimza 14 mg capsule
Romvimza 14 mg capsule is a prescription medicine containing Vimseltinib for oral use, marketed by Deciphera Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at controlled room temperature 20°C to 25°C (68°F to 77°F), excursions…
Key facts
- Active ingredient (INN)
- Vimseltinib
- Brand
- Romvimza
- Strength
- 14 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 1 carton
- Marketing authorisation holder
- Deciphera Pharmaceuticals
- Manufacturer
- Deciphera Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at controlled room temperature 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store capsules in their original blister packs until ready to be taken. Do not store ROMVIMZA in another container.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01EX Cancer medicines (antineoplastics), subgroup L01E, subgroup L01EX
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 14 February 2025
- Identifiers
- RxCUI 2705406, 2705412, 2705414 +3DailyMed set ID f73c7a62-9601-4df0-810f-100f515d79eaNDC 73207-302Application NDA219304
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 carton in 1 carton / 1 blister pack in 1 carton / 8 capsule in 1 blister pack | 73207-302-40 | Deciphera Pharmaceuticals | 14 February 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Vimseltinib
Clinical summary
Vimseltinib is a kinase inhibitor indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. MedsAcross supplies Vimseltinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about VimseltinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ROMVIMZA prescribing information (Deciphera Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Romvimza: European public assessment report (EPAR) · European Medicines Agency
Need Romvimza 14 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.